EGFR and non-small cell lung carcinoma: Then, a phase II “AURA2” study (NCT02094261) was initiated to enroll NSCLC patients with an EGFR-T790M mutation and acquired resistance to approved EGFR TKIs; the enrollment criteria were similar to those of the AURA study extension cohort.